Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.
D000375:Aging; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001085:Arabinofuranosylcytosine Triphosphate / Q000378:metabolism; D001215:Asparaginase / Q000008:administration & dosage*; D002648:Child; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004247:DNA / Q000096:biosynthesis; D003630:Daunorubicin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D006801:Humans; D007700:Kinetics; D007938:Leukemia / Q000188:drug therapy* / Q000378:metabolism; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008875:Middle Aged; D013997:Time Factors
D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate; D004247:DNA; D001215:Asparaginase; D003630:Daunorubicin